Solid Biosciences insider to sell 18,894 shares

Solid Biosciences insider David T. Howton filed a Rule 144 notice to sell 18,894 shares of common stock through E*TRADE Financial on NASDAQ, with an aggregate market value of $121,708.27.

Rhea-AI Filing Summary

Solid Biosciences insider David T. Howton filed a Rule 144 notice to sell 18,894 shares of common stock through E*TRADE Financial on NASDAQ, with an aggregate market value of $121,708.27.

These shares were acquired on 02/04/2026 via settlement of vested restricted stock units as compensation. Over the prior three months, Howton sold 4,932 shares for $25,202.52 on 12/03/2025 and 37,771 shares for $243,128.15 on 02/02/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SLDB Form 144 filing by David T. Howton disclose?

The filing discloses that insider David T. Howton intends to sell 18,894 shares of Solid Biosciences common stock under Rule 144. The shares were acquired from vested restricted stock units and are planned to be sold through E*TRADE Financial on the NASDAQ market.

How many SLDB shares is the insider planning to sell under Rule 144?

David T. Howton plans to sell 18,894 shares of Solid Biosciences common stock. The filing lists an aggregate market value of $121,708.27 for this block, based on the market price at the time the notice was prepared for the anticipated NASDAQ sale.

How were the 18,894 SLDB shares in the Form 144 acquired?

The 18,894 Solid Biosciences shares came from settlement of vested restricted stock units on 02/04/2026. The filing describes the nature of the acquisition as compensation from the issuer, with the same date listed for both acquisition and payment.

What recent SLDB stock sales has David T. Howton reported before this notice?

The filing notes two recent sales by David T. Howton: 4,932 shares of Solid Biosciences common stock on 12/03/2025 for $25,202.52, and 37,771 shares on 02/02/2026 for $243,128.15. These occurred within the three months preceding the new planned sale.

What trading details are provided for the new SLDB share sale?

The notice states the 18,894 Solid Biosciences shares are expected to be sold around 02/04/2026 on NASDAQ. E*TRADE Financial Corporation, based in Alpharetta, Georgia, is listed as the broker handling the transaction for the planned Rule 144 sale.

How many SLDB shares are outstanding according to this Form 144?

The filing reports 82,569,192 shares of Solid Biosciences common stock outstanding. This figure provides context for the size of the planned 18,894-share sale under Rule 144 relative to the company’s total common shares in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 07:42 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001529297
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Solid Biosciences Inc.
SEC File Number	001-38360
Address of Issuer	500 Rutherford Avenue Charlestown MASSACHUSETTS 02129
Phone	(617)-337-4680
Name of Person for Whose Account the Securities are To Be Sold	Howton David T
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	18894	121708.27	82569192	02/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/04/2026	Settlement of vested restricted stock units	Issuer			18894	02/04/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howton David T. C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	12/03/2025	4932	25202.52
Howton David T. C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	02/02/2026	37771	243128.15

144: Remarks and Signature

Remarks	The sale reported on this Form 144 was made to cover witholding taxes following the vesting of previously granted restricted stock units pursuant to a durable sale instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-cover-election. The sale does not represent a discretionary trade by Mr. Howton.
Date of Notice	02/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/16/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kimberly Cornwell as attorney-in-fact for David Tyronne Howton
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)